In preclinical studies, terazosin, an alpha1-adrenergic receptor antagonist and smooth muscle relaxer [98]; gelsemine [99]; and URB597, a fatty-acid amide hydrolase inhibitor [100] have also been effective in inhibiting chronic-stress-induced increases in IL-1β and reducing depression-like symptoms, similar to conventional antidepressants. The gene discussed is IL1B; the disease is depressive symptom measurement.